You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 10,555,902


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,555,902
Title:Stable fingolimod dosage forms
Abstract: The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
Inventor(s): Liu; Fangyu (Saratoga, CA)
Assignee: Handa Pharmaceuticals LLC (San Jose, CA)
Application Number:15/918,582
Patent Claims: 1. A method for treating multiple sclerosis comprising the step of administering to a patient in need of such treatment a solid oral dosage form comprising 0.1 mg to 1 mg of fingolimod lauryl sulfate salt and at least one pharmaceutically acceptable excipient, wherein following a single dose administration of the solid oral dosage form to healthy human adults under fasting conditions, the time to maximum fingolimod concentration (T.sub.max) is about 10 to about 35 hours, the dose adjusted maximum fingolimod concentration (C.sub.max/dose) is about 0.55 to about 1.5 ng/ml/mg, and the dose adjusted area under the plasma concentration-time curve (AUC.sub.0-.infin./dose) is about 125 to about 275 nghr/ml/mg.

2. The method of claim 1 wherein following a single dose administration of the solid dosage form to healthy human adults under fasting conditions, the time to maximum fingolimod concentration (T.sub.max) is about 12 to about 30 hours, the dose adjusted maximum fingolimod concentration (C.sub.max/dose) is about 0.60 to about 1.25 ng/ml/mg, and the dose adjusted area under the plasma concentration-time curve (AUC.sub.0-.infin./dose) is about 150 to about 250 nghr/ml/mg.

3. The method of claim 1 wherein the solid oral dosage form comprises about 0.5 mg of fingolimod.

4. The method of claim 1 wherein the solid oral dosage form is a tablet.

5. The method of claim 4 wherein said tablet disintegrates when tested using a USP Disintegration Apparatus in less than 1.5 minutes.

6. The method of claim 4 wherein the tablet is an orally disintegrating tablet or an orally dissolving tablet.

7. The method of claim 1 wherein the solid oral dosage formulation comprises about 0.2 mg to about 0.5 mg of fingolimod lauryl sulfate.

8. The method of claim 1 wherein the fingolimod lauryl sulfate salt is formed by: i) dissolving fingolimod or a pharmaceutically acceptable salt thereof in a suitable solvent; ii) dissolving an anionic lauryl sulfate or salt thereof in a suitable solvent; iii) allowing the dissolved fingolimod and dissolved lauryl sulfate to react and form the fingolimod lauryl sulfate salt wherein the molar ratio of fingolimod to lauryl sulfate is about 1 mole of fingolimod to about 3 moles or less of lauryl sulfate; and iv) removing the solvent.

9. The method of claim 8 wherein the molar ratio of fingolimod to lauryl sulfate is about 1 mole of fingolimod to about 0.5 to about 3 moles of lauryl sulfate.

10. The method of claim 8 wherein the molar ratio of fingolimod to lauryl sulfate is about 1 mole of fingolimod to about 0.5 to about 2 moles of lauryl sulfate.

11. The method of claim 8 wherein the molar ratio of fingolimod to lauryl sulfate is about 1 mole of fingolimod to about 0.5 to about 1.5 moles of lauryl sulfate.

12. The method of claim 8 wherein the fingolimod or pharmaceutically acceptable salt thereof employed in step (i) comprises fingolimod hydrochloride.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.